



PRESS RELEASE

Nobilon acquires rights to EBx™ cell lines from Vivalis for development, production and marketing of influenza vaccines

Boxmeer, the Netherlands and Nantes, France – May 30, 2007 – Nobilon and Vivalis announced today that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx® cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human influenza vaccines, including seasonal and pandemic.

The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include an upfront payment, milestone payments and royalties.

Dr. Han van den Bosch, director Research and Development at Nobilon stated: "All human influenza vaccines currently available on the market are produced on chicken eggs. Nobilon already utilizes modern cell culture production which has major advantages over egg production. We have several vaccines produced on mammalian cells in various stages of development. The Vivalis EBx® avian cell line provides us with additional means for influenza vaccine production in the near future".

Franck Grimaud, President of Vivalis, commented, "Vivalis is very pleased to enter in this agreement with Nobilon, a company that is strongly committed to develop a new generation of flu vaccine. Vivalis is confident that its different partners have the ability to capture a significant share of the human flu vaccine market which, with projected sales of over 3 billion US\$ in 2010, is a strategic market for Vivalis. The signature of this agreement further confirms that Vivalis' non-tumorigenic EBx® cell lines constitute an attractive alternative to embryonated eggs for the industrial production of a wide range of vaccines."

For more information, please contact:

Nobilon:

Monique Mols
Director media relations
Organon
Tel. +31-412-665440
E-mail: monique.mols@organon.com

Vivalis:

Frédéric Vole
Media Relations
Vivalis
Tel : +33 (0)2 28 07 37 10
fredericvole@vivalis.com

About Nobilon

Nobilon International BV, part of Organon, a biopharmaceutical business unit of Akzo Nobel, was founded in 2003, with production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines against infectious diseases, building on existing expertise within sister companies Intervet and Organon. Nobilon focuses on respiratory and traveller's diseases and one of its core expertises is large scale cell culture production of viruses, including influenza. Nobilon currently employs approximately 75 staff in production and R&D. www.nobilon.com

Safe Harbor Statement Organon*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com. The 2006 Annual Report on Form 20-F will be available in the second quarter of 2007.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.

About Vivalis

VIVALIS (Nantes, France) is a biopharmaceutical company specialised in vaccines and in viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants commercial licences to its proprietary EBx[®] embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.
- Recombinant therapeutic protein and monoclonal antibody expression systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary EBx[®] embryonic stem cell lines to manufacture recombinant therapeutic proteins.
- The build-up of a proprietary portfolio of vaccines and anti-viral molecules using VIVALIS' proprietary 3D-Screen platform.

Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n°2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, Novartis Vaccines, Meril and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster. www.vivalis.com

VIVALIS filed its Registration Document under the number I.07-077 dated 23 May 2007, with the Autorité des Marchés Financiers ("AMF"), for its listing on the Eurolist market of Euronext Paris.

The commercial licence described in this press release is reflected in the Registration Document. The Registration Document approved the 23 May 2007 under the number I.07-077 is available free of charge from Vivalis' head office, 6 rue Alain Bombard, 44800 Saint-Herblain, and in electronic form on the Company's web site (www.vivalis.com) and on the web site of the AMF (www.amf-france.org).

VIVALIS draws the readers' attention to the chapter 4 "Risks factors" of the Registration Document approved by the AMF.

This press release, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such press release in certain jurisdiction may constitute a breach of applicable laws and regulation. In particular:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any financial instruments in the United States. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. Any public offer of securities in the United States shall be made by means of a prospectus that may be obtained from the issuer containing detailed information regarding the Company, its management and financial statements. The Company does not intend to register this offering in all or in part or to make a public offer of securities in the United States.

This press release is not an invitation nor it is intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This document is directed only at (i) persons outside the United Kingdom; or (ii) persons in the United Kingdom that are "qualified investors" within the meaning of Article 2(1)(e) of Directive 2003/71/EC including any relevant implementing measure in each member state, that are also (a) persons authorised under FSMA or otherwise having professional experience in matters relating to investments and qualifying as investment professionals under article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order"); or (b) institutions or corporations qualifying as high net worth persons under Article 49(2)(a) to (d) of the Financial Promotion Order; or (c) any other persons to whom this document for the purposes of Section 21 of FSMA can otherwise lawfully be made (all such persons together being referred to as "Relevant Persons"). Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document.